Utility of thin-layer preparations in endometrial cytology: Immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions

Diagnostic Cytopathology

Volumn 36, Issue 4, 2008, Pages 216-223

  Norimatsu, Yoshiaki ^a,b   Miyamoto, Tomoyuki ^b   Kobayashi, Tadao K ^c   Oda, Tomohiro ^b   Moriya, Takuya ^d   Yanoh, Kenji ^e   Miyake, Yasuyuki ^b   Ohno, Eiji ^b  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b KURASHIKI UNIVERSITY OF SCIENCE AND THE ARTS   (Japan)

^c Medical Care Center   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e SUZUKA GENERAL HOSPITAL   (Japan)

Author keywords

Benign endometrium; Beta catenin; Endometrial cytology; Immunocytochemistry; p53; PTEN; Thin layer preparations

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CELL; ENDOMETRIUM CYTOLOGY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBODIES, NEOPLASM; BETA CATENIN; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41449094652     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20795     Document Type: Article

References (37)

1. Oncology Committee. Annual report on cervical, endometrial, and ovarian cancer. Acta Obst Gynaec Jpn 2004;58:1641-1726.
2. Austin RM, Ramzy I. Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. A review of accumulated data. Acta Cytol 1998;42:178-184.
3. Weintraub J, Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol 2000;22:52-59.
4. Michael CW, Hunter B. Interpretation of fine-needle aspirates processed by the ThinPrep technique: Cytologic artifacts and diagnostic pitfalls. Diagn Cytopathol 2000;23:6-13.
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
6. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
7. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Path 1997;81:228-232.
8. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577.
9. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2005;24:4783-4791.
10. Norimatsu Y, Kouda H, Kobayashi TK, et al. Utility of thin-layer preparations in the endometrial cytology: Evaluation of benign endometrial lesions. Ann Diagn Pathol (in press).
11. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
12. Zhou XP, Loukola A, Salovaara R, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002;161:439-447.
13. Saegusa M, Hashimura M, Yoshida T, Okayasu I. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-217.
14. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrial subtypes. Gynaecol Oncol 1996;61:165-172.
15. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
16. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001;10:237-242.
17. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Ziebold U, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000;85:2334-2338.
18. Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2004;130:161-168.
19. Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, Zheng W, Luleci G, Arici A. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab 2003;88: 5017-5026.
20. Zheng W, Baker HE, Mutter GL. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol 2004;92:1008-1013.
21. Mutter GL, Ince TA, Baak JPA, Kust G, Zhou X, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4314.
22. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;10:4783-4791.
23. Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003;45:1-14.
24. Sherman ME, Mazur MT, Kurman RJ. Benign disease of the endometrium. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract.5th ed. New York: Springer-Verlag; 2001. p 431-439.
25. Norimatsu Y, Moriya T, Kobayashi TK, et al. Immunohistochemical expression of PTEN and B-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol 2007;11:103-108.
26. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: Protein interactions and their implications for Cadherin function. J Cell Biochem 1996;61:514-523.
27. He TC, Sparks AB, Rago C, et al. Identification of c-Myc as a target of the APC pathway. Science 1998;281:1509-1512.
28. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-5527.
29. Zambetti GP, Levine AJ. A comparison of the biological activities of wild type and mutant p53. FASEB J 1993;7:855-865.
30. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
31. Lane DP. Cancer, p53, guardian of the genome. Nature 1992;358:15-16.
32. Nikaido T, Li SF, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-1253.
33. Shiozawa T, Xin L, Nikaido T, Fujii S. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecol Pathol 1997;16:348-353.
34. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: Positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003;34:471-478.
35. Quddus MR, Sung CJ, Zheng W, Lauchlan SC. p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999;35:44-49.
36. Cinel L, Polat A, Aydin O, Dusmez D, Egilmez R. Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium. Pathol Int 2002;52:384-389.
37. Norimatsu Y, Shimizu K, Kobayashi TK, et al. Endometrial glandular and stromal breakdown: II. Cytomorphology of papillary metaplastic change. Diagn Cytopathol 2006;34:665-669.